Free tool
Heavily traded stocks
We cover 52 companies whose typical session turns over more than $10.00M. The median market value in the group is $4.21B. Across the group, the median move over the past trading day is 0.00%. 96% of the 52 with a 200-day average trade above it. Price change over the past year runs from −20.0% to +254.2% across the middle 80 percent of the group, with a median of +49.0%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
52 of 7,336 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| MRK | Merck & Co., Inc. | $377.72B | Mega cap | +86.85% |
| AMGN | Amgen Inc. | $238.06B | Mega cap | +56.24% |
| TMO | Thermo Fisher Scientific Inc. | $234.31B | Mega cap | +30.17% |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% |
| CSL.AX | CSL Limited | $59.72B | Large cap | −16.37% |
| BDX | Becton, Dickinson and Company | $51.81B | Large cap | +25.97% |
| NTRA | Natera, Inc. | $48.53B | Large cap | +107.59% |
| IQV | IQVIA Holdings Inc. | $43.04B | Large cap | +38.51% |
| ILMN | Illumina, Inc. | $33.95B | Large cap | +125.88% |
| LH | Labcorp Holdings Inc. | $27.39B | Large cap | +21.14% |
| DGX | Quest Diagnostics Incorporated | $26.99B | Large cap | +38.12% |
| GMAB.CO | Genmab A/S | $20.69B | Large cap | +36.19% |
| ERF.PA | Eurofins Scientific SE | $14.64B | Large cap | +15.60% |
| CRL | Charles River Laboratories International, Inc. | $14.09B | Large cap | +81.27% |
| HALO | Halozyme Therapeutics, Inc. | $12.41B | Large cap | +46.30% |
| BIO | Bio-Rad Laboratories, Inc. | $10.40B | Large cap | +32.71% |
| RGEN | Repligen Corporation | $10.25B | Large cap | +51.67% |
| APGE | Apogee Therapeutics, Inc. | $10.21B | Large cap | +257.11% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% |
| TXG | 10x Genomics, Inc. | $8.37B | Mid cap | +358.35% |
| RHC.AX | Ramsay Health Care Limited | $8.27B | Mid cap | +50.11% |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −29.83% |
| CNTA | Centessa Pharmaceuticals plc | $6.27B | Mid cap | +143.24% |
| HAE | Haemonetics Corporation | $4.85B | Mid cap | +93.71% |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | +40.79% |
| ITGR | Integer Holdings Corporation | $4.25B | Mid cap | +15.84% |
| ANN.AX | Ansell Limited | $4.17B | Mid cap | +18.41% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | +181.38% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +55.97% |
| OGN | Organon & Co. | $3.62B | Mid cap | +50.67% |
| PLSE | Pulse Biosciences, Inc. | $3.43B | Mid cap | +203.47% |
| MRVI | Maravai LifeSciences Holdings, Inc. | $3.30B | Mid cap | +281.97% |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +73.50% |
| ZLAB | Zai Lab Limited | $2.92B | Mid cap | −20.06% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +61.71% |
| AMBU-B.CO | Ambu A/S | $2.69B | Mid cap | −19.13% |
| CDNA | CareDx, Inc. | $2.64B | Mid cap | +283.45% |
| RAPP | Rapport Therapeutics, Inc. | $2.52B | Mid cap | +250.70% |
| BAVA.CO | Bavarian Nordic A/S | $2.51B | Mid cap | −7.97% |
| ATRC | AtriCure, Inc. | $2.45B | Mid cap | +29.14% |
| ONT.L | Oxford Nanopore Technologies plc | $2.41B | Mid cap | −2.24% |
| EKTA-B.ST | Elekta AB (publ) | $2.20B | Mid cap | +26.10% |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | +254.61% |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% |
| PRGO | Perrigo Company plc | $2.05B | Mid cap | −36.05% |
| 366A.T | WELLNESS COMMUNICATIONS CORPORA | $89.79M | Micro cap | −23.84% |
| 4512.T | Wakamoto Pharmaceutical Co.,Ltd. | $67.16M | Micro cap | +1.97% |
| 4584.T | Kidswell Bio Corporation | $55.44M | Micro cap | −26.03% |
| 4583.T | Chiome Bioscience Inc. | $42.82M | Micro cap | −36.76% |
| PMI | Picard Medical, Inc. | $20.13M | Micro cap | +113.51% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.